Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced Urothelial Carcinoma (LUX-Bladder 1)
NCT02780687Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of afatinib in urothelial carcinoma (UC), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free Survival Rate at 6 Months. Started Jun 2016; status: completed.
02
Drugs
afatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02780687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780687.